UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000030703
Receipt number R000034915
Scientific Title Assessment of cardiac involvements in rheumatoid arthritis using a cardiac magnetic resonance approach: multicenter prospective study
Date of disclosure of the study information 2018/01/12
Last modified on 2021/01/08 15:40:32

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Assessment of cardiac involvements in rheumatoid arthritis using a cardiac magnetic resonance approach: multicenter prospective study

Acronym

Assessment of cardiac involvements in rheumatoid arthritis

Scientific Title

Assessment of cardiac involvements in rheumatoid arthritis using a cardiac magnetic resonance approach: multicenter prospective study

Scientific Title:Acronym

Assessment of cardiac involvements in rheumatoid arthritis

Region

Japan


Condition

Condition

rheumatoid arthritis(RA)

Classification by specialty

Clinical immunology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

In this study, we will consider the following items using non-invasive cardiac MRI.
to identify the frequency and the extent of cardiac involvement in RA patients who do not have any cardiac disorders

Basic objectives2

Others

Basic objectives -Others

to evaluate the effect of biologics and estimate the improvement of prognosis

Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

We explored the associations of cardiac MRI abnormalities with RA disease activity and severity measures.

Key secondary outcomes

We evaluate to detect the influence of Biologics in cardiac function


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

75 years-old >=

Gender

Male and Female

Key inclusion criteria

1)All rheumatic disease patients were over twenty years old and met the American College of Rheumatology criteria.
2)Cardiac symptoms were absent in all subjects.

Key exclusion criteria

Participants were excluded if they had prior self-reported, physician-diagnosed cardiovascular events or procedures, such as myocardial infarction, angioplasty, and CHF. Additional exclusions were diabetes (HbA1c>6.1), hypertension ((systolic blood pressure (BP) >140 mm Hg and/or diastolic BP>90 mm Hg), and dyslipidemia (LDL cholesterol levels >140 mg/dL, an HDL cholesterol level<40 mg/dL, or a triglyceride level>150 mg/dL).History of bronchoconstriction, contraindication to MRI, hypersensivity to gadolinium were absent in all subjects, and others in which the physician deemed inappropriate to enter the study.

Target sample size

40


Research contact person

Name of lead principal investigator

1st name Isamu
Middle name
Last name Yokoe

Organization

Nihon University School of Medicine

Division name

Division of Hematology and Rheumatology

Zip code

173-8610

Address

30-1 Oyaguchi Itabashi-Ward, Tokyo Japan 173-8610

TEL

0339728111

Email

yokoe@po.kyoundo.jp


Public contact

Name of contact person

1st name Hitomi
Middle name
Last name Kobayashi

Organization

Nihon University School of Medicine

Division name

Division of Hematology and Rheumatology

Zip code

173-8610

Address

30-1 Oyaguchi Itabashi-Ward, Tokyo Japan 173-8610

TEL

0339728111

Homepage URL


Email

pero1995@gmail.com


Sponsor or person

Institute

Nihon University School of Medicine

Institute

Department

Personal name



Funding Source

Organization

Nihon University School of Medicine

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Nihon University School of Medicine

Address

30-1 Oyaguchi Itabashi-Ward, Tokyo Japan 173-8610

Tel

0339728111

Email

yokoe@po.kyoundo.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2018 Year 01 Month 12 Day


Related information

URL releasing protocol


Publication of results

Partially published


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

No longer recruiting

Date of protocol fixation

2017 Year 10 Month 24 Day

Date of IRB

2019 Year 03 Month 15 Day

Anticipated trial start date

2018 Year 01 Month 10 Day

Last follow-up date

2022 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

All patients will be examined by contrast-enhanced CMR with cine MRI, tagging MRI on a 3.0 T MRI scanner. Multivariate analysis will be performed to assess the relationship between disease activities and biomarkers.
Using cine MRI and tagging MRI of 3.0 Tesla, we will analyze the relationship indicating myocardial disorder and the activity of RA. Since the 3.0 Tesla MRI is not available in our hospital, the examination will be performed at Yaesu clinic. During the observation period, the treatment of RA including the subscription of biological will be performed by the attending physician.


Management information

Registered date

2018 Year 01 Month 05 Day

Last modified on

2021 Year 01 Month 08 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000034915


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name